Watchlist TTOO T2 Biosystems 1.23 Focuses on in-vitro diagnostics ..Its T2 Magnetic Resonance Technology allows for the detection of pathogens..biomarkers and other abnormalities in various unpurified patient sample types Return On Equity Forecast to be 7,200% in Two Years Revenue Has Grown 43% per year Revenue forecast To Grow 12% per year TipRanks Strong Buy with Target price 3.13
Midnight News ENTA..46.39..Enanta Pharmaceuticals Announced This Morning New Data For EDP-721 An Oral hepatitis B Virus RNA Destabilizer Low Float 14 million TipRanks price Target 56.60
ACST...69..Up 29% pre-market Acasti Pharma Treatments For Cardiovascular Diseases\ Revenue forecast to Grow 434% per year
FTXP...0020 Foothills Exploration Announced Compliance and Corporate Update Oil and Gas Exploration company..today announced that it has been granted access to the OTC disclosure and News Service..This marks an important step for the Company towards becoming current on the OTC Pink sheets and ultimately back to OTCQB
Pennystocks.com Buy On Dip ENZC..16 Enzolytics Biotech developing and commercializing therapeutics for treatment of infectious diseases.This includes ITV-1 a tretment for HIV/AIDS..Only a few weeks ago it announced definitive plans to advance its ITV-1 anti HIV therapeutic in clinical trials throughout Europe Recently formed International Medical Partnersship with severalmajor European Companies this will help the distribution of ITV-1 in more than 27 Countries across Europe.
Throw Back Thursday Yesterday's Losers Lows and Highs IDRA 1.38 Down 13% L..1.31...H..1.71 PHIL .0136 D 29% L...0090...H....0158 LTNC .0112 D 24% L...010...H....0165 FNMA 1.52 D 32% mL..1.23...H...2.50 AVVH .0655 D 31% L...0553..H...0999 WSRC .1270 D 49% L....1210...H..2545 FMCC 1.41 D 37% L...1.21...H..2.46 TMXN .0120 D 23% L...0102...H...0172 PSWW .1450 D 31% L.....11..H...22 TOMDF .0329 D 25% L...0310...H.0460 MLND 1.14 D 17% L...1.11..H...1.24
Recent Heavy Insider Buying Someone Knows Something XAIR..6.08 Medical Device and Bio-Pharm..Treats Respiratory Tract Infections Low Float 17 million Revenue Forecast to Grow 309% TipRanks Strong buy Target price 10.93 CERE..12.56 Tackles Neuroscience Diseases TipRanks Moderate Buy target price 24.50 GEO..7.26 Real Estate Investment Trust Trading Below Intrinsic Value of 159.00 Return On equity 28% in three years Forecast to Grow 40% per year TipRanks Moderate buy Target price 11.63
Pre-Market King MRIN..Up 50%..2.57 Yesterday Marin Software..a leading provider of digital marketing has added ability to manage Instacart Ads to its Marinone Platform Very Low float 9.8 million
News At 9 SBEV...3.38 Splash Beverage Group Extends Reach Of Its Salt Tequila Brand..Engages With Distributing Giant Great Bay Distributors, Inc..To Drive Growth In Florida Markets..
News At 9:30 GTEH....0014 GenTech Successfully Closes NxTBar Acquisition Adding A Strong and Growing Brand With Broad Established Distribution Footprint That Includes GNC..Walmart.com..Amazon.com..TruNorth Canada and an extensive network of more than 2,000 brick-and-mortar locations across US
Stifel Analyst Doubles Price Target Of FULC 8.91 Today Fulcrum therapeutics Announced Results From ReDux4 Trial With Lusmapimod In Facioscapulohumeral Muscular Dystrophy Dmonstrating Slowed Disease Progression and Improved Function Considered Significantly Undervalued Revenue Has Frown Faster 1,600% Than US Industry Average Of 117% Revenue Forecast to Grow 27% Per Year Stifel Raised Target Price to 20.00 TiPRanks Strong Buy With target Price of 22.00
SRNE..Up 10% On News..9.90 Sorrento Just Received EUA Approval And Import License From Mexico Authority Cofepros for Covistix..Covid-19 Virus Rapid antigen Detection Test..And Plan Product Launch With Initial Shipments In July
Undervalued with Upside SNCR..2.69..Synchronos Tech Software and cloud networked synchronization platforms..Reported signing two contracts in southeast Asia..One contract eill deliver Synchronoss product to 25 Universities Float 37 million TipRanks Strong Buy Target price 7.73
TipRanks highlight Sorrento Firing On all Cylinders Closed Up 10% yesterday 10.00 On News Of Week Tuesday announced a multi-year Cooperative Research and Development Agreement With US Naval Reaearch Unit Navy chose Sorrento because Company has a pipeline bulging with prospective treatment diagnostics addressing coronavirus SRNE also announced enrollment for Brazilian Phase 2 Clinical Study of Abivertinib in hospitalized Covid-19 patients has been completed Also Mexican Regulatory Agency Cofrepris Offically Authorized Emergency Use of Covistix Company plans to establish a local Sorrento Mexico Operation Analyst HC Wainwright issues a continued Buy Rating for shares With a 30.00 Price Target
Watchlist SYRS..5.58 Syros Pharmaceuticals..Oncoing Phase 3 Study of its Sy-1425 RARA agonist potential among newly diagnosed unfit acute myelogenous leukemia patients. XERS..4.32 Xeris Phamaceuticals..Developes ready to use injectables for rare and orphan disease treatment GEE...6013 Job a Provider of Employment Services
News After The Bell RHHBY..46.60 Genetech's Actemra Received FDA Emergency Use Authorization For The Treatment Of covid-19 In Hospitalized Adults and Children
Buy and Hold ZEV..8.33 Lightning eMotors Offers two tracks.. Producing Electric Vehicles and Charging Stations Vehicles commercial..Cargo and passenger Vans..School and City Buses..Motor coaches Lightning Energy is company's Charging Station Segment Produces a series of EV Charging Stations and provides installation maintanence and support Company has sales backlog of $169 million and New Sales Pipeline of $807 million Incredible Low float of 2.1 million TipRanks Strong Buy Target Price 14.67
More Upside Analysts See growth for another 3-5 years PLTR..26.53..Palantir Technologies Is growing customer base and now accepting Bitcoin Provides Organizations with solutions to manage large disparate data sets in an attempt to gain insight and drive operational outcomes Market Cap 49 Billion Heavy Daily Volume
News At 9 VERU..8.22 Announced this morning Veru Enrolled First patient in Phase 3 Veracity Clinical Trial of Sabizabulin in Metastatic Castration Resistant And Androgen Receptor Targeting Agent Resistant Prostate Cancer Veru is a Bio-Pharm focused on Urology and Oncology TipRanks Strong Buy With Target Price of 21.33
